Headquartered in San Diego, CA Fiscal year ends December NASDAQ: IBRX immunitybio.com
ImmunityBio, Inc. (NASDAQ: IBRX) is a commercial-stage biotechnology company that develops and commercializes immunotherapies intended to activate the patient's immune system against cancer and infectious diseases.
Its core offering is the Cancer BioShield platform, anchored by ANKTIVA (nogapendekin alfa inbakicept). ANKTIVA is an IL-15 receptor superagonist antibody-cytokine fusion protein designed to stimulate NK cells, cytotoxic T cells, and memory T cells. The platform is complemented by:
- adenovirus-vectored vaccines
- allogeneic (off-the-shelf) and autologous NK-cell therapies
- additional immunomodulators
ANKTIVA in combination with BCG is the company's revenue-generating product. It is approved for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In October 2026 the FDA expanded the label to include high-grade papillary-only tumors. The product is approved or authorized in six regulatory jurisdictions covering 35 countries, including Israel through partner Rafa Laboratories. Commercial dosing has begun in Europe.
The company is pursuing a supplemental BLA in BCG-naïve NMIBC based on its QUILT-2.005 trial. Other clinical programs target metastatic non-small cell lung cancer, glioblastoma, and hematologic malignancies.
The company operates with a significant stockholders' deficit and is funded through a related-party convertible note, a revenue interest financing arrangement, and equity and warrant financings. Updated
A $77.9 million non-cash fair-value charge on ImmunityBio's related-party convertible note and warrants, triggered by its own rising stock price, blew out the quarterly loss. ANKTIVA revenue grew 53% year over year while missing expectations, and the FDA submission for BCG-naive bladder cancer is now the Q4 catalyst to watch.
The House GOP conference chair's spouse put the three biggest tickets into defense IT, chlorine chemicals and offshore drilling, each in the $15,000 to $50,000 range, while trimming Seagate. Nine buys across one September stretch, disclosed 28 days after the first trade, lands days after the Senate shelved a congressional trading ban.
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally…
ImmunityBio, Inc. (NASDAQ: IBRX) is a commercial-stage biotechnology company that develops and commercializes immunotherapies intended to activate the patient's immune system against cancer and infectious diseases. Its core offering is the Cancer BioShield platform, anchored by ANKTIVA (nogapendekin alfa inbakicept).
The Wall Street consensus 12-month price target for IBRX is $14.25. IBRX price prediction →
